AAAAAA
Results:
1-12
|
Results: 12
Authors:
Drukarch, B
van Muiswinkel, FL
Citation: B. Drukarch et Fl. Van Muiswinkel, Neuroprotection for Parkinson's disease: a new approach for a new millennium, EXPERT OP I, 10(10), 2001, pp. 1855-1868
Authors:
Tissingh, G
Berendse, HW
Bergmans, P
DeWaard, R
Drukarch, B
Stoof, JC
Wolters, EC
Citation: G. Tissingh et al., Loss of olfaction in de novo and treated Parkinson's disease: Possible implications for early diagnosis, MOVEMENT D, 16(1), 2001, pp. 41-46
Authors:
van Muiswinkel, FL
Riemers, FM
Peters, GJ
LaFleur, MVM
Siegel, D
Jongenelen, CAM
Drukarch, B
Citation: Fl. Van Muiswinkel et al., L-Dopa stimulates expression of the antioxidant enzyme NAD(P)H : quinone oxidoreductase (NQO) in cultured astroglial cells, FREE RAD B, 29(5), 2000, pp. 442-453
Authors:
van de Witte, SV
Groenewegen, HJ
Drukarch, B
Voorn, P
Citation: Sv. Van De Witte et al., Dynorphin modulates dopamine D1-receptor mediated turning behavior in 6-hydroxydopamine-lesioned rats, NEUROSCI L, 290(1), 2000, pp. 37-40
Authors:
Drukarch, B
van Muiswinkel, FL
Citation: B. Drukarch et Fl. Van Muiswinkel, Drug treatment of Parkinson's disease - Time for phase II, BIOCH PHARM, 59(9), 2000, pp. 1023-1031
Authors:
Vermeulen, RJ
Drukarch, B
Wolters, EC
Citation: Rj. Vermeulen et al., Dopamine D-1 receptor agonists: The way forward for the treatment of Parkinson's disease? (vol 11, pg 83, 1999), CNS DRUGS, 12(1), 1999, pp. 48-48
Authors:
Vermeulen, RJ
Drukarch, B
Wolters, EC
Stoof, JC
Citation: Rj. Vermeulen et al., Dopamine D-1 receptor agonists - The way forward for the treatment of Parkinson's disease?, CNS DRUGS, 11(2), 1999, pp. 83-91
Authors:
Andringa, G
Vermeulen, RJ
Drukarch, B
Renier, WO
Stoof, JC
Cools, AR
Citation: G. Andringa et al., The validity of the pretreated, unilaterally MPTP-treated monkey as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF81297, BEHAV PHARM, 10(2), 1999, pp. 163-173
Authors:
Andringa, G
Lubbers, L
Drukarch, B
Stoof, JC
Cools, AR
Citation: G. Andringa et al., The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF82958, BEHAV PHARM, 10(2), 1999, pp. 175-182
Authors:
Stoof, JC
Winogrodzka, A
van Muiswinkel, FL
Wolters, EC
Voorn, P
Groenewegen, HJ
Booij, J
Drukarch, B
Citation: Jc. Stoof et al., Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy, EUR J PHARM, 375(1-3), 1999, pp. 75-86
Authors:
Andringa, G
Drukarch, B
Leysen, JE
Cools, AR
Stoof, JC
Citation: G. Andringa et al., The alleged dopamine D-1 receptor agonist SKF 83959 is a dopamine D-1 receptor antagonist in primate cells and interacts with other receptors, EUR J PHARM, 364(1), 1999, pp. 33-41
Authors:
Dringen, R
Hamprecht, B
Drukarch, B
Citation: R. Dringen et al., Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cells, N-S ARCH PH, 358(6), 1998, pp. 616-622
Risultati:
1-12
|